Joint Formulary & PAD

Galantamine - Dementia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Not Specified
Associated Icons :
Restrictions / Comments :
Important

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.

Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).

PAD Profile

ChemicalSubstance :
Galantamine
Indication :
Dementia
Group Name :
Keywords :
AChE Inhibitors, acetylcholinesterase inhibitors, alzheimers disease, alzheimers dementia, Alzheimer's disease, Lewy Body dementia, Vascular dementia, Parkinson's dementia
Brand Names Include :
Reminyl XL, Acumor XL, Galsya XL, Consion XL, Elmino XL, Gaalin, Galzemic XL, Gatalin XL, Gazylan XL, Lotprosin XL, Luventa XL
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
4

Other Indications

Below are listed other indications that Galantamine is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Dementia.

Committee Recommendations (1)

Generic donepezil is the 1st-line acetylcholinesterase inhibitor for mild to moderate Alzheimer's disease.  Galantamine or rivastigmine are alternative AChE inhibitors. Galantamine is also a treatment option for dementia with Lewy bodies, vascular dementia and Parkinson's dementia.
See below for the local treatment pathways

Galantamine has been recommended as BLUE (with information sheet) for those patients who are stable and suitable for discharge from specialist care.  


AMBER shared care  will apply for the patients that are not suitable for discharge and who will continue to receive follow up by SABPT